BioSpace News Archive

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 203,333 new Ordinary shares of $.10 each in the Company. The New Ordinary Shares rank pari passu with the existing Ordinary shares in the Company.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s first quarter 2021 financial results will be released on Thursday, May 6, 2021.

- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), (the " Company ") today announced that its upcoming 2021 Annual General Meeting (the " Meeting ") will be held virtually at 12:00 p.m. Eastern Daylight Time

Hillrom announced financial results for its fiscal second quarter ended March 31, 2021, and raised its fiscal 2021 guidance.

Castle Biosciences Supports American Academy of Dermatology’s “Skin Cancer, Take a Hike! ™ " Steps Challenge for Skin Cancer Awareness Month The month-long fundraising event invites the public to help log 9,500 miles in honor of the approximately 9,500 people diagnosed with skin cancer every day

Single-Use H-SteriScopes™ Added to Olympus Bronchoscopic Portfolio, Offering Flexibility and Choice to Physicians Performing Advanced Procedures

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a US$15 million subordinated secured loan facility (the “ Loan Facility ”), which will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation Capital Inc.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Dr. Stephen Kaldor, one of the company’s co-founders, is not being nominated for re-election to the company’s Board of Directors when his term expires at the company’s 2021 annual meeting

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will be participating in the BofA Securities 2021 Virtual Health Care Conference.

Sales revenues amounted to € 219.6 million, in line with the previous year; EBITDA increased by 34%, reaching € 34 million.